FDA Authorized COVID Drugs Get New Advertising Abilities, Likely Necessitated By First Amendment
Pfizer and Merck indicate they may take advantage of new FDA decision that will give companies more flexibility to tout clinical trial results of COVID-19 therapeutics granted emergency use authorization.
You may also be interested in...
Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.
Marks opines on what sponsors would need to do to bring a ‘better’ vaccine to market in a NEJM interview. Meanwhile, CDC releases real world data on estimated bivalent booster efficacy.
Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit.